Caris Life Sciences Adds NYSE Texas Listing Effective June 17
CAI•Caris Life Sciences will begin trading its common stock on NYSE Texas under CAI on June 17, 2026, while maintaining its NASDAQ listing to broaden investor access. Headquartered in Irving, Texas, the precision medicine pioneer employs over 450 staff in the state and offers AI-driven molecular profiling.
1. Dual Listing Implementation
On June 17, 2026, Caris Life Sciences will commence dual trading of its common stock on NYSE Texas under the CAI ticker, while retaining its NASDAQ listing to expand liquidity and investor reach across U.S. markets.
2. Strategic and Regional Impact
The dual listing leverages Caris’ strong Texas presence—headquartered in Irving with over 450 local employees—to deepen engagement with state and national investors and reinforce its growth trajectory as a public company.
3. Advanced Precision Medicine Platform
Caris develops and commercializes AI-driven molecular profiling solutions—Whole Genome, Whole Exome and Whole Transcriptome Sequencing—to support diagnostics, therapy selection and drug development, underpinned by a large-scale multimodal clinico-genomic database.
